Keyphrases
Japan
100%
F Protein
100%
Cost-effectiveness Analysis
100%
Respiratory Syncytial Virus Infection
100%
Respiratory Syncytial Virus Vaccines
100%
Prefusion F
100%
Palivizumab
85%
Protein-based Vaccine
71%
Respiratory Syncytial Virus
42%
Protein-based
28%
Quality-adjusted Life Years
28%
Incremental Cost-effectiveness Ratio
28%
Medically Attended
28%
Pregnant Women
14%
Neonate
14%
Monoclonal Antibody
14%
High Risk
14%
Respiratory Infection
14%
Economic Outcomes
14%
Cost-effectiveness
14%
Outpatient Visits
14%
Gestational Age
14%
Emergency Department
14%
Healthcare Settings
14%
Vaccination
14%
Emergency Department Visits
14%
Active Immunization
14%
Dominant Strategy
14%
Premature Infant
14%
Payer Perspective
14%
Productivity Loss
14%
Markov Model
14%
Healthcare Payer
14%
Combined Strategy
14%
Vaccination in Pregnancy
14%
Intervention Costs
14%
Medication Cost
14%
Loss Cost
14%
Inpatient Hospitalization
14%
Cost-effective Strategy
14%
Respiratory Syncytial Virus Hospitalization
14%
Maximum Price
14%
Pharmacology, Toxicology and Pharmaceutical Science
Respiratory Syncytial Virus Infection
100%
Palivizumab
100%
Respiratory Syncytial Virus Vaccine
100%
Protein-Based Vaccine
83%
Human Respiratory Syncytial Virus
66%
Prematurity
33%
Monoclonal Antibody
16%
Respiratory Tract Infection
16%